Over the past three decades, there has been a startling increase in the prevalence of obesity across the U.S., at least ...

Thank you for standing by. My name is John, and I’ll be your conference operator today. At this time I would like to welcome everyone to the Allurion Third Quarter Earnings Call. All lines have been ...

Nearly three quarters of U.S. adults are overweight or obese, according to a sweeping new study. The findings have ...

US equities overcame brief spells of volatility to reach new all-time highs in Q3 as underlying earnings growth remained positive. Read more here.

Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 – – Cash ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

The rise in type 2 diabetes cases globally presents opportunities for growth in the market for GLP-1 drugs like Ozempic and ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...

In response to the FDA’s shortage decision, Hims & Hers is launching a new GLP-1 tracker, allowing patients to self-identify, provide ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

GLP-1 medications, like Ozempic and Wegovy, mimic natural hormones in the body that regulate blood sugar and insulin levels. They’re used to treat type 2 diabetes and obesity. These drugs curb the ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associ ...